Multipolymer microsphere delivery of SARS-CoV-2 antigens

Shahjin, Farah; Patel, Milankumar; Machhi, Jatin; Cohen, Jacob D.; Nayan, Mohammad Ullah; Yeapuri, Pravin; Zhang, Chen; Waight, Emiko; Hasan, Mahmudul; Abdelmoaty, Mai Mohamed; Dash, Prasanta K.; Zhou, You; Andreu, Irene; Gendelman, Howard E.; Kevadiya, Bhavesh D.

doi:10.1016/j.actbio.2022.12.043

Cited by 12 publications

(4 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biodegradable polymer micro-cells are stable, biocompatible, non-toxic, biodegradable, and injectable. Also, they can continuously provide encapsulated antigen by delaying its release ( 119 ). However, the organic compounds used to create biodegradable mono-polymer microspheres may have an adverse effect on the activity of bioactive peptides.…”

Section: Drug Delivery Methods For Sars-cov-2 Inhibitory Peptides Fro...mentioning

confidence: 99%

Recent advances in the exploration and discovery of SARS-CoV-2 inhibitory peptides from edible animal proteins

Kong,

Wang,

Zhong

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19), is spreading worldwide. Although the COVID-19 epidemic has passed its peak of transmission, the harm it has caused deserves our attention. Scientists are striving to develop medications that can effectively treat COVID-19 symptoms without causing any adverse reactions. SARS-CoV-2 inhibitory peptides derived from animal proteins have a wide range of functional activities in addition to safety. Identifying animal protein sources is crucial to obtaining SARS-CoV-2 inhibitory peptides from animal sources. This review aims to reveal the mechanisms of action of these peptides on SARS-CoV-2 and the possibility of animal proteins as a material source of SARS-CoV-2 inhibitory peptides. Also, it introduces the utilization of computer-aided design methods, phage display, and drug delivery strategies in the research on SARS-CoV-2 inhibitor peptides from animal proteins. In order to identify new antiviral peptides and boost their efficiency, we recommend investigating the interaction between SARS-CoV-2 inhibitory peptides from animal protein sources and non-structural proteins (Nsps) using a variety of technologies, including computer-aided drug approaches, phage display techniques, and drug delivery techniques. This article provides useful information for the development of novel anti-COVID-19 drugs.

show abstract

Section: Drug Delivery Methods For Sars-cov-2 Inhibitory Peptides Fro...mentioning

confidence: 99%

Recent advances in the exploration and discovery of SARS-CoV-2 inhibitory peptides from edible animal proteins

Kong,

Wang,

Zhong

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

show abstract

“…However, challenges still exist in using the above-mentioned processes for nano- or microparticle formulation as controlling size, size distribution, shape, and batch-to-batch variation remains unmanageable. Moreover, encapsulating biologics using these techniques is considerably more challenging due to the inherent nature of proteins and biologics to interact with the polymer surface, as well as concerns about the stability of the biologics [ 248 , 249 ].…”

Section: La Arv Deliverymentioning

confidence: 99%

Polymer Delivery Systems for Long-Acting Antiretroviral Drugs

Nayan,

Panja,

Sultana

et al. 2024

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs hold promise for improved regimen adherence and reduced toxicities. Current examples include Cabenuva, Apretude, and Sunlenca. Each is safe and effective. Alternative promising DDSs include implants, prodrugs, vaginal rings, and microarray patches. Each can further meet patients’ needs. We posit that the physicochemical properties of the formulation chemical design can optimize drug release profiles. We posit that the strategic design of LA DDS polymers will further improve controlled drug release to simplify dosing schedules and improve regimen adherence.

show abstract

“…The immune response of mRNA LNPs encapsulated in hyaluronan hydrogels was maintained after being stored at room temperature for two weeks [ 63 ]. PCL/PLGA/PLLA microspheres were used to deliver SARS-CoV-2 antigens, where no visible particle degradation or changes in porosity patterns were observed during storage at 4 °C for 180 days [ 64 ]. For example, a potent self-amplifying RNA (saRNA) vaccine against SARS-CoV-2 that is stable at room temperature has been developed.…”

Section: Vaccine Typesmentioning

confidence: 99%

Just Keep Rolling?—An Encompassing Review towards Accelerated Vaccine Product Life Cycles

Stiefel,

Zimmer,

Schloßhauer

et al. 2023

Vaccines

View full text Add to dashboard Cite

In light of the recent pandemic, several COVID-19 vaccines were developed, tested and approved in a very short time, a process that otherwise takes many years. Above all, these efforts have also unmistakably revealed the capacity limits and potential for improvement in vaccine production. This review aims to emphasize recent approaches for the targeted rapid adaptation and production of vaccines from an interdisciplinary, multifaceted perspective. Using research from the literature, stakeholder analysis and a value proposition canvas, we reviewed technological innovations on the pharmacological level, formulation, validation and resilient vaccine production to supply bottlenecks and logistic networks. We identified four main drivers to accelerate the vaccine product life cycle: computerized candidate screening, modular production, digitized quality management and a resilient business model with corresponding transparent supply chains. In summary, the results presented here can serve as a guide and implementation tool for flexible, scalable vaccine production to swiftly respond to pandemic situations in the future.

show abstract

Multipolymer microsphere delivery of SARS-CoV-2 antigens

Cited by 12 publications

References 98 publications

Recent advances in the exploration and discovery of SARS-CoV-2 inhibitory peptides from edible animal proteins

Recent advances in the exploration and discovery of SARS-CoV-2 inhibitory peptides from edible animal proteins

Polymer Delivery Systems for Long-Acting Antiretroviral Drugs

Just Keep Rolling?—An Encompassing Review towards Accelerated Vaccine Product Life Cycles

Contact Info

Product

Resources

About